Farletuzumab + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-Sensitive Ovarian Cancer in First Relapse
Conditions
Platinum-Sensitive Ovarian Cancer in First Relapse
Trial Timeline
Mar 19, 2015 → Aug 13, 2020
NCT ID
NCT02289950About Farletuzumab + Placebo
Farletuzumab + Placebo is a phase 2 stage product being developed by Eisai for Platinum-Sensitive Ovarian Cancer in First Relapse. The current trial status is completed. This product is registered under clinical trial identifier NCT02289950. Target conditions include Platinum-Sensitive Ovarian Cancer in First Relapse.
What happened to similar drugs?
0 of 1 similar drugs in Platinum-Sensitive Ovarian Cancer in First Relapse were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02289950 | Phase 2 | Completed |
Competing Products
4 competing products in Platinum-Sensitive Ovarian Cancer in First Relapse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OSE2101 + Pembrolizumab 25 MG/ML [Keytruda] | Merck | Phase 2 | 39 |
| Ipilimumab | Bristol Myers Squibb | Phase 2 | 35 |
| AK112 low dose + Chemotherapy + Olaparib + AK112 high dose | Akeso | Phase 2 | 42 |
| ZL-2306(nirapairb) + Placebos | Zai Lab | Phase 3 | 30 |